Sort by
Refine Your Search
-
Listed
-
Category
-
Program
-
Field
-
mission. Externally, the role will build momentum with government, industry, cultural institutions, philanthropy, alumni and community partners to unlock new possibilities, amplify impact and elevate the
-
appointment until 31 December 2027 Remuneration: Pro-rata of $86,195 - $116,981 pa Level A (plus 17% employer superannuation) Make your mark in research at a world top 50 University Join our collaborative
-
communications priorities Use research and sentiment analysis to inform decisions Uphold brand, risk and compliance standards Build strong partnerships with senior leaders and stakeholders Drive continuous
-
progression can make early identification and risk assessment challenging. The increasing availability of clinical, demographic, hormonal, metabolic and longitudinal health data provides opportunities
-
related discipline. Demonstrated experience in DNA and RNA library construction for Illumina-based sequencing, with knowledge of methodologies including WGS, RNA-seq, ATAC-seq and EM-seq. Hands
-
building secure, reliable, and responsible AI systems? We are seeking a talented and driven Research Fellow (Level A) to join our dynamic team and make high-impact contributions to the critical fields
-
to work with modern enterprise networking technologies, contribute to continual improvement and help build a future-ready network capability, while sharing knowledge and supporting the development of others
-
more about Monash . Join the pursuit of our purpose to build a better future for ourselves and our communities - #ChangeIt with us. Monash supports flexible and hybrid working arrangements. We have a
-
of leaders, you build high-performing teams, develop capability and influence effectively across complex stakeholder environments. Combining sound judgement, commercial acumen and intellectual
-
. This study aims to construct a transparent, non-invasive predictive framework combining machine learning and explainable AI (XAI) to differentiate malignant from benign pelvic masses, stratify patient risk